ReviewExperimental & molecular medicine2021
Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions.
Review in Experimental & molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 183 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
183 citing papers in PubMed, 2 syntheses or guidelines pooled it, 271 citations in OpenAlex.
- Unraveling the Controversy: The Causal Link Between Osteoarthritis and Alzheimer's Disease.Brain and behavior · 2025Pooled it
- The causal effect of cytokine cycling levels on osteoarthritis: a bidirectional Mendelian randomized study.Frontiers in immunology · 2023Pooled it
- Trial
- Associations between folate intake and knee pain, inflammation mediators and comorbid conditions in patients with symptomatic knee osteoarthritis.BMC musculoskeletal disorders · 2024Trial
- Leukocytes Do Not Influence the Safety and Efficacy of Platelet-Rich Plasma Injections for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Controlled Trial.The American journal of sports medicine · 2024Trial
- Immunomodulatory thermosensitive hydroxypropyl chitin hydrogel platform maintains cartilage-synovium homeostasis for enhanced osteoarthritis therapy.Bioactive materials · 2026Article
- Co-assembly of dipeptide and hydrophobic drug in hyaluronic acid through Schiff base reaction for the treatment of osteoarthritis.Pharmaceutical science advances · 2026Article
- Redox-immune modulating gadolinium vanadate based nanozymes for osteoarthritis therapy.Materials today. Bio · 2026Article
- Spatial multi‑omics identifies an SPP1+ macrophage‑driven anti‑apoptotic niche in osteoarthritis synovium via the SPP1‑CD44 axis.International journal of molecular medicine · 2026Article
- Integrative Proteome-Wide Mendelian Randomization and Multi-Omics Analysis Identify ADM and CFH as Candidate Genes for Osteoarthritis.Biomedicines · 2026Article
- Curcumin as a natural therapeutic agent for osteoarthritis: molecular mechanisms, preclinical evidence, clinical applications, and future perspectives.Inflammopharmacology · 2026Review
- Experimental models of osteoarthritis: Advances, limitations and rational selection for translational research.Journal of orthopaedic translation · 2026Review
- Inflammation-Responsive Nanocolloidal Hydrogel Enables On-Demand Gene Activation for Osteoarthritis Therapy.Advanced healthcare materials · 2026Article
- Cysteine metabolism dysregulation promotes ferroptosis in osteoarthritis: Insights from multi-species bioinformatics and experimental validation.Journal of orthopaedic translation · 2026Article
- Innate immune sensor NOD2 promotes cartilage degradation and osteoarthritis progression by stabilizing TRAF6 in chondrocytes.JCI insight · 2026Article
- Liposomal multimodal theranostics for bone disorders: from rational responsive delivery and biomimetic strategies to clinical translation.Journal of nanobiotechnology · 2026Review
- Validation of an AI-based automated Knee Inflammation MRI Scoring System for assessing bone marrow lesions.EULAR rheumatology open · 2026Article
- Astragalus Polysaccharides Attenuate LPS-Induced Degenerative Responses in Primary Rat Chondrocytes linked to the NLRP3/CASPASE-1 Axis.Journal of musculoskeletal & neuronal interactions · 2026Article
- Exosomes and Small Extracellular Vesicles as an Alternative to Mesenchymal Stromal Cell Therapy in Knee Osteoarthritis: From Biological Rationale to Clinical Evidence.International journal of molecular sciences · 2026Review
- Application Strategies of Bone Marrow Mesenchymal Stromal Cells in Bone-Related Diseases.Cell proliferation · 2026Review
123 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is the most common form of arthritis. It is characterized by progressive destruction of articular cartilage and the development of chronic pain and constitutes a considerable socioeconomic burden. Currently, pharmacological treatments mostly aim to relieve the OA symptoms associated with inflammation and pain. However, with increasing understanding of OA pathology, several potential therapeutic targets have been identified, enabling the development of disease-modifying OA drugs (DMOADs). By targeting inflammatory cytokines, matrix-degrading enzymes, the Wnt pathway, and OA-associated pain, DMOADs successfully modulate the degenerative changes in osteoarthritic cartilage. Moreover, regenerative approaches aim to counterbalance the loss of cartilage matrix by stimulating chondrogenesis in endogenous stem cells and matrix anabolism in chondrocytes. Emerging strategies include the development of senolytic drugs or RNA therapeutics to eliminate the cellular or molecular sources of factors driving OA. This review describes the current developmental status of DMOADs and the corresponding results from preclinical and clinical trials and discusses the potential of emerging therapeutic approaches to treat OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.